Little is known about trafficking of heme from its sites of synthesis to sites of heme-protein assembly. We describe an integral membrane protein that allows trapping of endogenous heme to elucidate trafficking mechanisms. We show that CcsBA, a representative of a superfamily of integral membrane proteins involved in cytochrome c biosynthesis, exports and protects heme from oxidation. CcsBA has 10 transmembrane domains (TMDs) and reconstitutes cytochrome c synthesis in the Escherichia coli periplasm; thus, CcsBA is a cytochrome c synthetase. Purified CcsBA contains heme in an ''external heme binding domain'' for which two external histidines are shown to serve as axial ligands that protect the heme iron from oxidation. This is likely the active site of the synthetase. Furthermore, two conserved histidines in TMDs are required for heme to travel to the external heme binding domain. Remarkably, the function of CcsBA with mutations in these TMD histidines is corrected by exogenous imidazole, a result analogous to correction of heme binding by myoglobin when its proximal histidine is mutated. These data suggest that CcsBA has a heme binding site within the bilayer and that CcsBA is a heme channel.
H
eme is the cofactor for proteins such as hemoglobins and myoglobins that carry oxygen and for the cytochromes, which are involved in energy conversion. The transmembrane trafficking of heme from its site of synthesis, inside the mitochondrion, chloroplast, or bacterium, to these proteins is poorly understood (1) . There is emerging evidence that organisms use specific transporters to traffic heme (1-4) and porphyrins (5) into cells and intracellularly, although trapping of heme in such integral membrane proteins has not yet been accomplished. Because all cytochromes c function and are synthesized in the prokaryotic periplasm, mitochondrial intermembrane space, or chloroplast lumen, heme must be delivered to these sites, yet the molecular mechanisms of delivery are unknown. Cytochrome c synthesis is carried out by one of three pathways (systems I, II, and III) (6) (7) (8) (9) (10) and requires the formation of two thioether bonds between the cysteines of a CXXCH motif in the apoprotein and the vinyl groups of heme. For this covalent ligation to occur, the heme must be reduced (Fe 2ϩ ) (11, 12) , but the mechanism of heme reduction in vivo is unknown. One pathway for this synthesis (system II), originally discovered from genetic work in Chlamydomonas reinhardtii (13) (14) (15) (16) (17) , Bacillus subtilis (18) (19) (20) , and Bordetella pertussis (21, 22) , is present in plant chloroplasts and many bacteria ( Fig. 1) (6) . We reconstituted the function of this pathway in recombinant Escherichia coli, demonstrating that in an appropriate thiol reducing environment only the CcsB and CcsA proteins are required for periplasmic cytochromes c biogenesis (23) (see Fig. S1 for model). CcsA has a highly conserved, tryptophan-rich region called the WWD domain that is proposed to be involved in heme binding, but no member of this WWD superfamily has been purified (16, (24) (25) (26) . Each WWD superfamily member is an integral membrane protein with two conserved histidine residues in periplasmic loops flanking the WWD domain that have been proposed to act as axial ligands to heme iron (16, 24, 26, 27) . Mutations in these two conserved histidines in CcsA and the putative system I synthetase CcmF result in a loss of function (16, 27) . Due to a lack of biochemical analysis of this family, important questions remain unanswered, including whether WWD superfamily members indeed bind heme and, if so, the location of the binding site or sites and whether these proteins export heme to the external surface, and, if so, by what mechanism.
Although most bacterial and plant genomes encode individual ccsB and ccsA genes, in some organisms, including Helicobacter hepaticus, the CcsB and CcsA proteins are naturally fused into a single large ORF, ccsBA. We show that CcsBA from H. hepaticus has 10 transmembrane domains (TMDs) and reconstitutes cytochrome c synthesis in the Escherichia coli periplasm; thus, CcsBA is a cytochrome c synthetase. Use of this CcsBA recombinant fused protein has facilitated purification, trapping of endogenous heme, and characterization of heme export. We demonstrate that CcsBA binds reduced (Fe 2ϩ ) heme in an ''external heme binding domain'' composed of the two external histidines flanking the WWD domain. When either of these histidines is mutated, the absorption spectrum of the heme in CcsBA is dramatically perturbed, and unlike WT, the heme iron is oxidized (Fe 3ϩ ). These perturbations show that these histiAuthor contributions: E.R.F. and R.G.K. designed research; E.R.F. performed research; E.R.F. and R.G.K. analyzed data; and E.R.F. and R.G.K. wrote the paper. Fig. 1 . Representative distribution of systems I, II, and III among the bacteria and archaea. The chloroplasts and mitochondria are also included. The system number is noted in parentheses after each group name. Some classifications contain organisms that do not make cytochromes c and thus do not have system proteins. Relative relationships between groups are based on 16S rRNA sequences. Several groups include organisms that may have either system I or system II; this scenario may become more common as more genome sequences become available.
dines are the axial ligands to the heme iron and that they play a critical role in protecting the heme from oxidation. We also show that two conserved TMD histidines in CcsBA are required for translocation of reduced heme from its site of synthesis in the cytoplasm to the external heme binding domain. The function of CcsBA with mutations in these TMD histidines is corrected by exogenous imidazole, a histidine side chain mimic. This result is similar to the correction of a proximal histidine mutant of myoglobin (H93G) where imidazole binds in the H93G ''cavity'' to restore heme binding (28) . These data suggest a low-affinity heme binding site inside CcsBA and that CcsBA forms a channel for the translocation of reduced heme across the membrane. Fig. 2A) , and we were able to purify significant amounts of recombinant protein (see below). CcsBA was expressed as a functional Nterminal fusion to GST, solubilized in n-dodecyl ␤-D-maltoside (DDM), and affinity-purified to Ͼ95% purity. In addition to the full-length protein (133 kDa), three polypeptides are observed (Fig.  2B ) whose identities were determined by N-terminal sequencing and anti-GST immunoblot. The smallest polypeptide (Ϸ26 kDa) is GST. The two major polypeptides (labeled GSTCcsB* and CcsA* in Fig. 2B ) are the products of a single proteolytic event in the periplasmic domain of CcsB (Fig. 3A) . The larger (Ϸ70 kDa) is GST-tagged CcsB*, and the smaller (Ϸ55 kDa) is called CcsA*. The CcsA* polypeptide copurifies with GSTCcsB* with equimolar stoichiometry, certainly due to the tight complex that CcsB and CcsA form, as shown by immunological methods in B. pertussis and C. reinhardtii (16, 21) . The natural proteolytic susceptibility of CcsB has facilitated analysis and localization of heme within CcsA*, and we later use this susceptibility as a diagnostic tool for studies on mutant CcsBA proteins. Purified CcsBA preparations are red, suggesting a heme protein. A chemiluminescent stain to detect heme ( Fig. 2C ) of the CcsBA preparation shows that free heme is present, dissociated by SDS, in addition to some heme associated with the CcsA* polypeptide that disappears upon boiling. This suggests that the CcsA portion of CcsBA binds heme noncovalently.
Results

Purification of the
Heme in CcsBA Is Reduced b-Type Heme. Using UV-visible absorption spectroscopy on purified CcsBA, we demonstrate that a member of the WWD superfamily binds heme and that the heme is reduced (Fe 2ϩ ). CcsBA exhibits the spectrum of a reduced, b-type heme protein with an ␣ peak at 562 nm, a ␤ peak at 528 nm, and a Soret peak at 416 nm, which did not change after reduction with sodium dithionite (Fig. 2D ). The heme in CcsBA is oxidized (to Fe 3ϩ ) by ammonium persulfate, diminishing the ␣ and ␤ absorptions and blue-shifting the Soret peak by 5 nm to 411 nm. The spectrum of the heme from CcsBA extracted in pyridine (Fig. 2E) shows that it is b-type (noncovalently bound) heme (29) , as is present, for example, in myoglobin (Fig. 2E , Inset).
Characterization of the External Heme Binding Domain: His-761 and
His-897 Are Axial Ligands. We next determined the features in CcsBA that constitute the heme binding domain. We experimentally established the membrane topology of the H. hepaticus CcsBA protein, identifying the locations of conserved residues (Fig. 3A, red) . For topology data and analysis, see Fig. S2 and legend. The topology is consistent with previous experimentally determined topologies for CcsA from Mycobacterium leprae and C. reinhardtii (16, 24) . Of particular interest are the conserved WWD domain and four absolutely conserved histidines (starred) that could serve as axial ligands to a heme iron. His-761 and His-897 flank the WWD domain in the periplasm. To determine which residues of CcsBA are involved in heme binding (i.e., where the heme is trapped), we generated a mutant for each of these and a triple mutant for three conserved residues in the WWD domain (-WGWD-in Fig. 3A , with WWD changed to alanines). The mutants, designated CcsBA(H761A), CcsBA(H897A), and CcsBA(WWD), are not functional for cytochromes c biogenesis (Fig. 3B) . The CcsBA(WWD), CcsBA(H761A), and CcsBA(H897A) proteins purify with similar amounts of heme to WT (Fig. 3 C and D, Top) and similar stabilities, with the same GSTCcsB* to CcsA* stoichiometry ( Fig. 3 C and D Lower) . The CcsBA(WWD) protein has a spectrum identical to that of WT, with reduced (Fe 2ϩ ) heme (Fig. 3E) . The CcsBA(H761A) and CcsBA(H897A) proteins, however, purify in the oxidized (Fe 3ϩ ) state (Fig. 3F) ; no ␣ or ␤ peaks are detectable, and the Soret maximum is at 415 nm. Upon addition of sodium dithionite, the heme is reduced, with sharp peaks at 560 and 531 nm, and the Soret peak red-shifted to 426 nm, a maximum wavelength nearly 10 nm longer than that of WT. Spectra of pyridine-extracted CcsBA(H761A) and CcsBA(H897A) (Fig. 3F Insets) show that b-type heme is present, like W T. These results show that, although CcsBA(H761A) and CcsBA(H897A) still bind heme, the environment of that heme is altered when one of the histidine ligands is missing.
Transmembrane Histidines His-77 and His-858 Are Involved in Channeling Heme to the External Heme Binding Domain. We hypothesized that the conserved His-77 and His-858 residues, located in TMDs close to the cytoplasmic surface (Fig. 3A) , may bind heme in a channel for export. Neither CcsBA(H77A) nor CcsBA(H858A) is functional for cytochromes c biogenesis (Fig. 4A) . We determined whether mutations in His-77 and His-858 might affect the ability of CcsBA to deliver heme to the external heme binding domain. The CcsBA(H77A) and CcsBA(H858A) proteins are stable (Fig. 4 B and C Lower) , but strikingly, the CcsBA(H858A) protein has no heme detectable by chemiluminescent heme stain (Fig. 4B Upper) or spectral detection, indicating at least 100-fold less heme is present than in the WT CcsBA (30) . The CcsBA(H77A) protein has approximately 4-fold less heme than WT by heme stain (Fig. 4C Upper) and pyridine extraction analysis (Fig. 4D) . Spectral characteristics of CcsBA(H77A) are similar to those of WT except that more heme is in the oxidized state (Fig. 4E) . We propose that the TMDs that include the conserved His-77 and His-858 associate in the membrane with both histidines participating in the formation of a low-affinity heme binding site (see Discussion). Imidazole Complementation of TMD Histidine Mutants. In a second approach to investigate the presence of a TMD heme binding site, we tested our recombinant CcsBA histidine mutants for restoration of function by exogenous imidazole. A recombinant form of myoglobin that is mutated at its proximal axial ligand, His-93, does not bind heme (28) . The myoglobin H93G cavity mutant is complemented intermolecularly by growth in the presence of 10 mM imidazole (28) . The imidazole-reconstituted cavity mutant has an absorption spectrum like that of WT myoglobin, and crystal structures show imidazole bound in the H93G cavity. Although the CcsBA external heme binding site mutants are not corrected, both weak binding site TMD histidine mutants are fully restored with 10 mM imidazole (Fig. 5) . The TMD histidine mutants are corrected more dramatically under anaerobic (Fig. 5A ) than aerobic (Fig. 5B ) growth, suggesting that heme must be protected from oxidation as it traverses the membrane, consistent with the fact that some of the heme in CcsBA(H77A) is oxidized.
Discussion
Here, we present the CcsBA cytochrome c synthetase as a paradigm of heme transport, processing, and cytochrome c synthesis. This purification of a WWD domain protein provides proof that this superfamily binds heme. The function of two pairs of conserved histidine residues was also determined. These four histidines are present in all CcsB/A proteins examined (Fig. 3A and Table S1 ), including three fused CcsBA proteins from Wolinella succinogenes that recognize different apocytochrome c motifs (i.e., CXXCH, CXXCK, and CX 15 CH) (31, 32) and CcsB/A from eukaryotes such as C. reinhardtii, where they have been shown to be required for function (13, 16) . Spectra of the H. hepaticus CcsBA(H761A) and CcsBA(H897A) proteins have dramatically different Soret maxima compared with those of WT for both the reduced (427 and 416 nm) and the oxidized (415 and 411 nm) forms, indicating a change in axial ligands to the heme iron, as noted for other heme proteins (33, 34) . The ␣ maxima of the mutant proteins (560 nm) is also blue-shifted by 2 nm, consistent with the results of mutating a histidine axial ligand to alanine in cytochrome b 562 (35) . We conclude that His-761 and His-897 compose the external heme binding domain in what likely constitutes the active site for the CcsBA cytochrome c synthetase. Purification of these mutant proteins in the oxidized rather than the reduced form demonstrates that these histidines also protect the heme iron from the oxidizing environment of the periplasm. This protection is critical because only reduced (Fe 2ϩ ) heme can form correct covalent bonds with an apocytochrome c (11, 12) . Moreover, the compartments where cytochrome c synthesis occurs (the bacterial periplasm or chloroplast lumen) can be quite oxidizing environments for heme compared with the sites of heme biosynthesis. Two conserved histidines in CcsBA, His-77 and His-858, are in TMDs. A pair of conserved TMD histidines has been shown to be required for the function of an ABC transporter for heme uptake from Shigella dysenteriae (3). His-77 and His-858 in CcsBA are required not only for synthetase function but also for translocation of heme to the external heme binding domain. Our data also suggest that CcsBA TMD3 (with His-77) is positioned close to TMD8 (with His-858); therefore, TMDs in CcsB may associate with TMDs in CcsA. We suggest that His-77 and His-858 compose an initial low-affinity binding site for reduced (Fe 2ϩ ) heme at the cytoplasmic face of a channel formed by CcsBA. In this respect, crystal structures of various channels and transporters indicate that the presence of a low-affinity binding site near a channel opening, in addition to the expected highaffinity binding site, might be more common than once thought (36) . Intermolecular complementation of CcsBA(H77A) and CcsBA(H858A) function with exogenous imidazole was used as a second approach to establish that His-77 and His-858 are axial ligands to heme. Inability to correct the CcsBA(H761A) and CcsBA(H897A) mutants in the external heme binding domain with imidazole might be due to ligand switching that occurs at this active site (see below) or the inability of free imidazole to bind in these cavities. There are at least three examples of recombinant, soluble heme proteins (myoglobin, horseradish peroxidase, and guanylate cyclase) corrected for heme binding by imidazole when their histidine ligands are mutated (28, 37, 38) . CcsBA is an example of a membrane protein or putative channel that is chemically complemented for function by imidazole when histidine ligands are mutated. The myoglobin H93G cavity mutant has become a model for heme and heme-iron interaction with ligands, in part due to exogenous complementation with small molecules that expand the genetic code (e.g., refs. 28 and 39-41). We envision the CcsBA(H77A) and CcsBA(H858A) mutants as similar models for channel functions and interactions with heme. Enhanced imidazole complementation under anaerobic growth conditions implicates these TMD histidines in redox protection of heme as well.
On the basis of the results of this study, we propose a mechanistic model for cytochromes c biogenesis by CcsBA (Fig.  3A and Fig. S1 ). The CcsBA TMDs associate in the membrane to form a channel for translocation of heme. Reduced heme from the cytoplasm binds in a low-affinity binding site, liganded by His-77 (TMD3) and His-858 (TMD8), and then translocates to the high-affinity external heme binding domain, with iron liganded and protected from oxidation by His-761 and His-897. We expect that a heme concentration gradient drives passive translocation but cannot rule out active translocation. The WWD domain orients the heme, positioning the vinyl groups in close proximity to the reduced thiols of the apocytochrome c CXXCH motif (perhaps positioned by the periplasmic domain of CcsB) for spontaneous thioether bond formation. Ligand switching occurs, with the histidine of the CXXCH motif replacing either His-761 or His-897 as the fifth axial heme ligand. The sixth axial ligand of cytochrome c subsequently forms upon folding into its mature, native form, which could provide the energy for heme release from the high-affinity binding site.
Materials and Methods
Bacterial Growth Conditions. E. coli were grown aerobically in LB media (Difco) at 22°C with shaking at 300 rpm. Antibiotic concentrations used are as follows: 50 g mL Ϫ1 carbenicillin (Carb), 20 g mL Ϫ1 chloramphenicol (Cm), and 100 g mL Ϫ1 kanamycin (Kan).
Plasmid Construction. E. coli strains TB1 and HB101 were used as the host strains for cloning. Construction of pRGK332 was described in ref. 23 .
pGEX-4T-1-derived vectors (GE Healthcare) have an N-terminal fusion to GST. Expression is under the control of the isopropyl ␤-D-thiogalactopyranoside (IPTG)-inducible tac promoter. Construction of pRGK368 was described in ref. 42 .
CcsBA:PhoA fusions were generated by PCR amplification of pRGK368 using oligonucleotide primer pGEXNotI and the individual CcsBA:PhoA fusion oligonucleotide primers listed in Table S2 . In-frame fusions to alkaline phosphatase A (PhoA) were created at the amino acid numbers indicated in the primer names. The phoA sequence from pRGK323 (22) was amplified using oligonucleotide primers PhoALI XhoI and PhoAR NotI. Both products were digested with XhoI and NotI and ligated.
CcsBA:GFP fusions were generated as described in ref. 43 . The ccsBA coding region of pRGK368 was amplified by PCR using oligonucleotide primer HhCcsBA fwd NdeI and the CcsBA:GFP fusion primers listed in Table S2 to generate fusions at the amino acid numbers indicated in the primer names. PCR products were digested with NdeI and BamHI and ligated to pWALDO digested with NdeI and BamHI (43, 44) .
The H761A, H897A, WWD, and H858A mutant versions of pRGK368 were generated by first amplifying with the appropriate mismatch primer (listed in Table S2 ) and HH ccsBA Rv2 to generate a short PCR product. This product was gel-purified and then used in a second amplification with HH ccsBA Lv2. The H77A mutant was generated by first amplifying with the CcsBA H77A mismatch primer and HH ccsBA Lv2. The gel-purified product was used with HH ccsBA Rv2 for the final amplification. The final, full-length products were digested with BamHI and XhoI and inserted into pGEX-4T-1 as for pRGK368. pRGK368 was the template for all amplifications. Constructs were sequenced to confirm the mutation.
Cytochrome Reporter Assays. Constructs were transformed into RK103 (⌬ccm) containing pRGK332 (cytochrome c 4, di-heme, B. pertussis). After induction with 1 mM IPTG and 0.2% arabinose, cells were harvested by centrifugation, and the pellet was resuspended in 200 L of B-PER (Pierce) to lyse the cells and extract protein. Total protein concentration was determined by bicinchoninic acid assay (Pierce), and 20 g was analyzed using chemiluminescence (heme stain).
Protein Expression, Purification, and Analysis. Heme stains, immunoblots, and protein purification were performed as described in refs. 23 and 45. The free heme stain assay is exposure of the SDS/PAGE dye front (free heme is Ϸ616 Da) with chemiluminescent reagent. For expression, C43 E. coli (46) containing the CodonPlus RIL plasmid (Stratagene) grown for 8 h at 37°C in 5 mL of LB-Carb-Cm were used to inoculate 1-L cultures that were grown overnight (12-15 h) at 22°C and induced with 1 mM IPTG for 5.5 h. Cells were harvested and frozen at Ϫ80°C for at least 30 min. Cells were thawed, resuspended in 10 mM Tris⅐HCl, pH 7.5, with 1 mM phenylmethylsulfonyl fluoride, and sonicated to disrupt membranes. The crude sonicate was centrifuged to clear cell debris, and then membranes were harvested from the supernatant by centrifugation at 310,000 ϫ g for 1 h 15 min. Membrane pellets were suspended in GST bind/wash buffer (4.3 mM Na 2HPO4, 1.47 mM KH 2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.3) and solubilized with 1% DDM. Solubilized membranes were purified over GST resin (Novagen), washed 3 times with 15 mL of GST bind/wash buffer, and eluted with 20 mM reduced glutathione in 50 mM Tris⅐HCl pH 8, 0.1% DDM. Yields were 0.3-0.5 mg of Ͼ95% pure protein per liter of culture.
Spectral Analysis. UV-visible absorption spectra were recorded using a Shimadzu UV-2101PC UV-VIS scanning spectrophotometer at room temperature. Resolution is Ϯ1 nm based on the manufacturer's specifications and empirical testing with standard proteins such as myoglobin. Chemically reduced spectra were generated by adding a few grains of sodium dithionite (sodium hydrosulfite) to the sample. Chemically oxidized spectra were generated by adding a few grains of ammonium persulfate. Pyridine hemochrome analysis was performed as described in ref. 29 with the following volume modifications: 50 L of sample was combined in a 100-L cuvette with 50 L of stock solution containing 200 mM NaOH, 40% pyridine (by volume), and 0.6 mM K 3Fe(CN)6. Sodium dithionite was added to generate reduced spectra. Heme concentrations were determined as described, yielding heme-to-protein ratios of 0.25-0.4 heme per CcsBA.
Alkaline Phosphatase and GFP Activity Assays. CcsBA:PhoA and CcsBA:GFP fusion constructs were transformed into BL21(DE3) cells. Alkaline phosphatase assays were performed as described in ref. 24 using a SpectraMax Plus 384 plate reader (Molecular Devices). GFP assays were performed as described in ref. 43 . GFP fluorescence emission was detected using a SpectraMax Gemini XS microtitre plate reader (Molecular Devices) with the excitation filter at 485 nm and emission filter at 525 nm. Mean activities for both assays were determined from at least three independent experiments. Imidazole Complementation. Aerobic imidazole complementation assays were performed as described above for cytochrome c 4 reporter assays with a few modifications. Cells were grown in the presence of 1 or 10 mM imidazole, pH 7, in LB-Carb-Cm media. After induction with 1 mM IPTG, cells were allowed to express for 1 h before the reporter was induced with 0.2% arabinose. Heme stain analysis was performed on 40 g of total protein (B-PER fraction) subjected to SDS/PAGE. Anaerobic imidazole complementation assays were performed as described above using 12.5-mL cultures (inoculated with 1 mL of aerobically grown overnight culture) that were allowed to grow for 3 h before IPTG induction and 4 h after arabinose induction.
